TOL-463

DRUG2 trials

Sponsors

Toltec Pharmaceuticals, LLC, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Bacterial VaginosisVulvovaginal Candidiasis

Phase 2

TOL-463 Phase 2 Study for Vaginitis

CompletedNCT02866227

Toltec Pharmaceuticals, LLCBacterial Vaginosis, Vulvovaginal Candidiasis

Start: 2016-07-15End: 2017-06-10Updated: 2018-03-09

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

CompletedNCT03930745

National Institute of Allergy and Infectious Diseases (NIAID)Bacterial Vaginosis

Start: 2019-09-09End: 2021-12-06Updated: 2023-02-22

Related Papers

Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial

Clinical Infectious Diseases2018-07-0478 citations